Tiny study aims to predict which throat lesions turn cancerous
NCT ID NCT07508319
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at genetic and immune changes in laryngeal dysplasia, a precancerous condition of the voice box. Researchers will compare tissue samples from 3 patients to see if certain immune cells (TILs) differ between low-risk and high-risk lesions. The goal is to find markers that predict progression to cancer, which could improve monitoring and early treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could help identify which patients with laryngeal dysplasia are at highest risk of developing cancer, enabling earlier intervention.
- What could go wrong
- This is a very small, early observational study with only 3 participants. It is not testing a treatment, so it may not lead directly to any new therapy or change in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 3 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study will recruit 150 consecutive, untreated LDy patients, potentially within a multicenter framework.
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histopathological diagnosis of laryngeal dysplasia. * Age \>18 years and informed consent. Exclusion Criteria: * Prior surgical, radiotherapeutic, or oncologic treatments for head and neck regions. * Congenital or acquired immunodeficiency disorders. * Synchronous malignancies. * Immunosuppressive therapy. * Age \<18 years or absence of research consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Head neck cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
European Institute of Oncology
RECRUITINGMilan, MI, 20141, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radiation plus targeted antibody tested in older head and neck cancer patients
- Can a guided missile for chemo hit tumors harder and spare healthy tissue?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an immunotherapy combo shrink throat tumors before surgery?
- New study: can early palliative care help head and neck cancer patients suffer less?
- New lozenge aims to ease radiation mouth sores for hours